PanneauLab1-300x288Created in 2009 at the Cordeliers Center the team focused on the study of the physiopathology of B-cell malignancies, with a special interest in the regulation of programmed cell death (PCD) in chronic lymphocytic leukemia (CLL). Santos A. Susin and Florence Nguyen-Khac lead actually the team:

Dr. Susin (DR1, CNRS) has published more than 135 manuscripts on mitochondria, PCD and its mechanisms. Overall, these papers have given rise to more than 25,500 citations (~900 citations/year; Average Citations per Item: 190) and an h-index: 70 (Web of Science, July 2017). He is a co-inventor of 5 patent applications with international extension. A translational analysis has extended Dr Susin’s research into a general assessment of the causes of apoptotic drug resistance in CLL. Dr. Susin has coordinated projects for the ANR, INCa, ARC, FRM, Fondation de France, Association L. Fugain, and Ligue Cancer and he also serves as a reviewer in more than 30 scientific journals.

Pr. Nguyen-Khac (PU-PH, GHPS) is an expert in biological investigation of CLL and a reference for clinical trials in B lymphoproliferative diseases. She has published more than 90 manuscripts with an h-index: 29 (Web of Science, July 2017). Pr. Nguyen-Khac is part of the scientific committee of the French CLL group (FILO). Pr. Nguyen-Khac has developed a dedicated pipeline of genomic analyses (mutations, gains, losses, …), is the head of the Groupe Francophone de Cytogénétique Hématologique, and the director of the teaching department of Hematology at Université Paris 6 (UPMC).

Scientific production. The team is a reference in the field of hematological malignancies, with 170 peer-reviewed publications in the last 5 years, receiving 2435 citations (~400 citations/year). Of the 46 reviews, a number of opinion articles and exhaustive reviews have become references in the field; 4 Editorial comments, 12 technical papers, 1 book, 7 book chapters, and 4 patents with international extension complete our scientific production.

Academic reputation. Members of the team got relevant recognition on an international level with 65 abstracts/oral communications, 75 communications in international and national conferences published in prestigious hematological journals, and 106 seminars/presentations invites.

– Since 2012, the PIs of the team participated in 29 grants from governmental and private foundations.

– The members of the team attracted during the last 5 years 14 PhD students, presenting at least 1 first authorship paper, and trained over 12 master and 3 Erasmus students. Moreover, our team manages medical students in the lab (4 external/10 residents/year) and in the clinical department (15 external/8 residents/year). As to teaching, the team contributes substantially to medical studies (2d, 3d, 5th year), Master 1, Master 2, Diplômes universitaires, and Diplôme d’études spécialisées en Hématologie: 204 h/year.

– Impact on the public health. The research activity of our group has important impact on the management of patients suffering from hematological diseases. On the one hand, the discoveries of the team, based on studies performed in large cohorts of patients, identify new biomarkers that are important for the diagnosis and set-up of therapeutic strategies. On the other hand, our basic findings propose the introduction of new drugs to specifically eliminate the malignant cells. Our team is also involved in translating new technological developments into the field of innovative diagnostics in hematology, by ensuring assay standardization as well as organizing workshops and quality certification plans for many laboratories worldwide.

Our new team has participated in 124 peer-reviewed manuscripts and 46 reviews since 2012, thus attesting to the international recognition and relevance of the work developed by the team